The MUKDEN 01 clinical trial represented a significant step in this direction, evaluating the efficacy of a new therapeutic strategy that concurrently inhibits ER, HER2, and cell cycle signaling pathways in HR+/HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.